Next Article in Journal
Social Media Behavior and Emotional Evolution during Emergency Events
Next Article in Special Issue
Association of Mortality-Related Risk Factors in Patients with COVID-19: A Retrospective Cohort Study
Previous Article in Journal
The Feasibility of Using Machine Learning to Classify Calls to South African Emergency Dispatch Centres According to Prehospital Diagnosis, by Utilising Caller Descriptions of the Incident
Previous Article in Special Issue
Cutaneous Manifestations in SARS-CoV-2 Infection—A Series of Cases from the Largest Infectious Diseases Hospital in Western Romania
Article

Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience

1
Sub-Intensive Care Unit, Department of Respiratory Pathophysiology and Rehabilitation Monaldi–A.O. Dei Colli, 80131 Naples, Italy
2
Emergency Unit, Department of Infectious Diseases, Cotugno Hospital, 80131 Naples, Italy
3
UOC Medicina, Buonconsiglio Fate Bene Fratelli Hospital of Naples, 80123 Naples, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: David Price
Healthcare 2021, 9(9), 1108; https://doi.org/10.3390/healthcare9091108
Received: 30 May 2021 / Revised: 29 July 2021 / Accepted: 11 August 2021 / Published: 27 August 2021
Background: Antiviral treatment is a hot topic regarding therapy for COVID-19. Several antiviral drugs have been tested in the months since the pandemic began. Yet only Remdesivir obtained approval after first trials. The best time to administer Remdesivir is still a matter for discussion and this could also depend upon the severity of lung damage and the staging of the infection. Methods: We performed a real-life study of patients hospitalized forCOVID-19 and receiving non-invasive ventilation (NIV). In this single-center study, a 5 day course of Remdesivir was administered as compassionate use. Further therapeutic supports included antibiotics, low molecular weight heparin and steroids. Data collection included clinical signs and symptoms, gas exchange, laboratory markers of inflammation, and radiological findings. Major outcomes were de-escalation of oxygen-support requirements, clinical improvement defined by weaning from ventilation to oxygen therapy or discharge, and mortality. Adverse drug reactions were also recorded. All data were collected during hospitalization and during a 20-day follow up after treatment. Results: 51 patients were enrolled. A global clinical improvement was recorded in 22 patients (43%) at 12 days, and 36 (71%) at 20 days; in particular, at 12 days, 27 patients (53%) also had a de-escalation of oxygen-support class from a therapeutic point of view. Remdesivir use was associated with a lower hazard ratio for clinical improvement in the elderly (older than 70 years) and in subjects with more extensive lung involvement (total severity score at HRCT of more than 14). The 20-day mortality was 13%. Conclusions: Results demonstrated that Remdesivir is associated with an improvement in clinical, laboratory and radiological parameters in patients with severe COVID-19 and showed an overall mortality of 13%. We conclude that, in this cohort, Remdesivir was a beneficial add-on therapy for severe COVID-19, especially in adults with moderate lung involvement at HRCT. View Full-Text
Keywords: antiviral; SARS-CoV2; ARDS; NIV; CPAP antiviral; SARS-CoV2; ARDS; NIV; CPAP
Show Figures

Figure 1

MDPI and ACS Style

Simioli, F.; Nicoletta, C.; Valentino, M.R.; Martino, M.; Annunziata, A.; Carannante, N.; Di Micco, P.; Fiorentino, G. Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. Healthcare 2021, 9, 1108. https://doi.org/10.3390/healthcare9091108

AMA Style

Simioli F, Nicoletta C, Valentino MR, Martino M, Annunziata A, Carannante N, Di Micco P, Fiorentino G. Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. Healthcare. 2021; 9(9):1108. https://doi.org/10.3390/healthcare9091108

Chicago/Turabian Style

Simioli, Francesca, Carmine Nicoletta, Maria R. Valentino, Maria Martino, Anna Annunziata, Novella Carannante, Pierpaolo Di Micco, and Giuseppe Fiorentino. 2021. "Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience" Healthcare 9, no. 9: 1108. https://doi.org/10.3390/healthcare9091108

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop